Published in Medical Letter on the CDC and FDA, August 18th, 1997
"In the absence of 1) pre-exposure or post-exposure prophylaxis, 2) recommendations that are unique for hepatitis C virus (HCV) to prevent HCV transmission to others, and 3) effective therapy for most persons with chronic hepatitis C, the overall public health benefit associated with the identification of HCV infections in healthcare workers will be limited," the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.